October 11, 2026 
6 min read
Back to Blog
William Alden, MD, PhD | Medical Peptide & Fatty Acid Series
Metabolic and Diabetes: The GLP-1 and GIP Agonists
By William Alden, MD, PhD | Medical Peptide, Regenerative & Fatty Acid Series
The incretin peptides have reshaped how physicians treat type 2 diabetes and obesity, and they rank among the most consequential drug classes of the past decade. As a physician-scientist who works with these agents as metabolic and cardiometabolic tools, I stress that their power makes disciplined patient selection, careful monitoring, and responsible sourcing all the more important. This expanded discussion covers the approved agents, the emerging pipeline, mechanisms of action, regulatory nuances including compounding controversies, and practical clinical framing.
Key Agents in This Class
Semaglutide (Ozempic, Wegovy, Rybelsus)
. A GLP-1 receptor agonist that stimulates glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying, and reduces appetite via hypothalamic GLP-1 receptors. Available as once-weekly injectable (Ozempic for diabetes, Wegovy for weight management) and as an oral tablet (Rybelsus). Also approved to reduce cardiovascular event risk in type 2 diabetes. FDA-approved.
Tirzepatide (Mounjaro, Zepbound).
Dual GIP and GLP-1 receptor agonist that co-activates both incretin receptors, amplifying insulin response and satiety signaling beyond single GLP-1 agonism. Demonstrates the strongest glucose and weight effects among currently approved agents; also approved for obesity-related obstructive sleep apnea. FDA-approved.
Liraglutide (Victoza, Saxenda).
GLP-1 receptor agonist with a fatty-acid side chain that enables albumin binding and an approximately 13-hour half-life. Stimulates insulin, suppresses glucagon, reduces appetite, and has demonstrated cardiovascular mortality reduction in the LEADER trial. FDA-approved for diabetes and weight management.
Dulaglutide (Trulicity).
GLP-1 receptor agonist fused to an IgG4 Fc fragment for once-weekly dosing. Shares the core insulinotropic and glucagon-suppressing pathway; also reduces major cardiovascular events. FDA-approved.
Exenatide (Byetta, Bydureon) and lixisenatide (Adlyxin). Earlier-generation GLP-1 agonists. Exenatide is synthetic exendin-4 derived from Gila monster saliva—the first approved GLP-1 agonist. Lixisenatide is short-acting with pronounced post-meal glucose lowering via gastric emptying delay. FDA-approved.
Pramlintide (Symlin) and setmelanotide (Imcivree).
Pramlintide is a synthetic amylin analog that slows gastric emptying, suppresses post-meal glucagon, and promotes satiety; used as an adjunct to insulin. Setmelanotide is an MC4R agonist approved for specific genetic obesity syndromes (POMC, PCSK1, LEPR deficiency and Bardet-Biedl). FDA-approved.
Pipeline agents (retatrutide, survodutide, mazdutide, cagrilintide, CagriSema, amycretin, efpeglenatide, orforglipron).
Next-generation candidates include triple GIP/GLP-1/glucagon agonists (retatrutide has shown unprecedented weight-loss percentages in Phase 2), dual agonists, long-acting amylin analogs, fixed combinations, and the first oral small-molecule GLP-1 agonist (orforglipron). These remain investigational.
Evidence and Regulatory Status
Most marketed agents are FDA-approved for type 2 diabetes, chronic weight management, or cardiovascular risk reduction. The newest combinations and triple agonists remain in Phase 2 or 3 trials. Compounded semaglutide and tirzepatide have been a major regulatory flashpoint; shortage listings have shifted eligibility over time. I use only appropriately sourced, lawful product obtained through licensed channels. Patients and clinicians should verify current compounding status against official FDA guidance, as the landscape continues to evolve.
Frequently Asked Questions
Are these agents only for diabetes?
No. Several are approved for chronic weight management independent of diabetes status, and others carry cardiovascular risk-reduction indications. Selection depends on the primary therapeutic goal, comorbidities, and tolerability.
What about compounded versions?
Compounding status for these peptides has been contested and has shifted with drug-shortage listings and subsequent FDA actions. Only lawful, properly sourced pharmaceutical-grade product obtained via a licensed provider should be considered. Research-use-only material is never appropriate for human administration.
How do dual and triple agonists differ mechanistically?
Single GLP-1 agonists primarily enhance insulin secretion, suppress glucagon, slow gastric emptying, and reduce appetite. Adding GIP co-agonism further amplifies insulinotropic and satiety effects. Adding glucagon receptor agonism introduces energy-expenditure and hepatic-fat-reduction components. These broader receptor profiles explain the progressively larger metabolic effects seen in clinical trials.
Clinical Perspective
This is a powerful and fast-moving class. The clinical priority is matching the right agent to the right patient considering glycemic control, weight goals, cardiovascular risk, gastrointestinal tolerability, and injection versus oral preferencewhile monitoring for adverse effects and never compromising on how the product is sourced. As newer multi-agonists advance, the evidence bar for safety and long-term outcomes must remain high.
About the Author
William “Wes” Alden, MD, PhD, is a physician-scientist and internist whose career spans academic medicine, federal clinical research, community healthcare, and medical philanthropy. His work sits at the intersection of laboratory science and bedside care, and his writing consistently returns to one theme: regenerative and metabolic therapies deserve both open-minded use and rigorous scientific and regulatory scrutiny. This series surveys the major categories of therapeutic peptides and healthful fatty acids, one blog at a time, with an emphasis on honest evidence and clear regulatory status.
Clinical Perspective
This content is for general education and reflects Dr. Alden’s professional perspective. It is not medical advice and does not create a doctor-patient relationship. Individual results vary, and many agents discussed are not FDA-approved for the uses described. Several peptides are not FDA-approved and have an evolving federal compounding status; products labeled for research use only are never appropriate for use in people. Most fatty acids discussed are foods or dietary supplements and are not FDA-approved to treat any condition. Any peptide or compounded agent should be used only through a licensed provider, with appropriately sourced pharmaceutical-grade material. Readers should consult a qualified healthcare professional about their own situation before pursuing any treatment.
Educational content reflecting Dr. Alden’s professional perspective. Not medical advice. Several agents named are not FDA-approved and some have an evolving compounding status. See the full disclosure accompanying this series.
